轻型卒中或高危短暂性脑缺血发作后1年结局:韩国多中心卒中登记分析
基于韩国多中心卒中登记数据库,纳入症状发作7天内就诊的轻型缺血性卒中或高危短暂性脑缺血发作患者9506例,评估3个月及1年血管事件风险,并按出院时抗栓策略比较临床特征与事件率。结果显示当代二级预防策略下后续血管事件率较低,未采用阿司匹林单药者基线风险更高、事件率更高。
要点
- 3个月主要结局累计事件率5.9%,1年为9.3%
- 出院时95.2%接受抗栓治疗,86.2%接受他汀治疗
- 非阿司匹林策略或无抗栓者基线风险更高、事件率至少高1.5倍
核心结论
- 基于全面诊断评估的当代二级卒中预防策略,可能促成韩国真实世界临床实践中较低的后续血管事件率。
研究设计与样本
- 研究为韩国多中心卒中登记数据库分析,纳入症状发作7天内就诊的轻型缺血性卒中或高危短暂性脑缺血发作患者9506例。
- 按出院时抗栓策略分组,比较临床特征与事件率。
主要发现
- 3个月主要结局(卒中复发、心肌梗死或全因死亡的复合终点)累计事件率为5.9%,卒中复发为4.3%,主要血管事件为4.6%,全因死亡为2.0%。
- 1年时对应值分别为主主要结局9.3%、卒中复发6.1%、主要血管事件6.7%、全因死亡4.1%。
- 接受非阿司匹林抗栓策略或无抗栓药的患者基线风险特征更高,临床事件结局的事件率至少为阿司匹林单药者的1.5倍。
关键数值与推荐
- 93.8%的患者接受血管造影评估,72.7%接受心脏评估,25.1%存在颅内动脉症状性狭窄或闭塞。
- 出院时95.2%接受抗栓药(抗血小板联合治疗37.1%,抗凝15.3%),86.2%接受他汀。
临床怎么用
- 对轻型缺血性卒中或高危短暂性脑缺血发作患者应进行全面诊断评估并规范抗栓与他汀治疗,以降低后续血管事件风险。
- 出院时抗栓策略的选择需结合患者基线风险,非阿司匹林单药或无抗栓者事件率更高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Patients with minor ischemic stroke or transient ischemic attack are at high risk of recurrent stroke and vascular events, which are potentially disabling or fatal. This study aimed to evaluate contemporary subsequent vascular event risk after minor ischemic stroke or transient ischemic attack in Korea. METHODS: Patients with minor ischemic stroke or high-risk transient ischemic attack admitted within 7 days of symptom onset were identified from a Korean multicenter stroke registry database. We estimated 3-month and 1-year event rates of the primary outcome (composite of stroke recurrence, myocardial infarction, or all-cause death), stroke recurrence, a major vascular event (composite of stroke recurrence, myocardial infarction, or vascular death), and all-cause death and explored differences in clinical characteristics and event rates according to antithrombotic strategies at discharge. RESULTS: Of 9506 patients enrolled in this study, 93.8% underwent angiographic assessment and 72.7% underwent cardiac evaluations; 25.1% had symptomatic stenosis or occlusion of intracranial arteries. At discharge, 95.2% of patients received antithrombotics (antiplatelet polytherapy, 37.1%; anticoagulation, 15.3%) and 86.2% received statins. The 3-month cumulative event rate was 5.9% for the primary outcome, 4.3% for stroke recurrence, 4.6% for a major vascular event, and 2.0% for all-cause death. Corresponding values at 1 year were 9.3%, 6.1%, 6.7%, and 4.1%, respectively. Patients receiving nonaspirin antithrombotic strategies or no antithrombotic agent had higher baseline risk profiles and at least 1.5× higher event rates for clinical event outcomes than those with aspirin monotherapy. CONCLUSIONS: Contemporary secondary stroke prevention strategies based on thorough diagnostic evaluation may contribute to the low subsequent vascular event rates observed in real-world clinical practice in Korea.
引用
- Park HK, Kim BJ, Han MK, et al. One-Year Outcomes After Minor Stroke or High-Risk Transient Ischemic Attack: Korean Multicenter Stroke Registry Analysis. Stroke. 2017. PMID: 28974634. doi:10.1161/STROKEAHA.117.018045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。